Damora Therapeutics
Price chart
Anonymous reader poll. Unscientific, not investment advice.
✦ StockVane Quant Insights how this is computed
- Below its 200-day average or in the bottom third on momentum — the strategy is out of it.
- Signal has read SELL for 2 months.
- Its last 5 Sell calls were actually followed by a +67% average gain three months out - this one has bounced back faster than the signal expected.
- Recent price momentum is +5.2% on average (3-month/1-year).
- Main-fund capital flow has been a net outflow over the last 45 sessions.
- Short interest has risen to 7.6% of float.
- Analyst tilt is Buy.
- Price is above its 20-day average and above its 60-day average.
- The 20-day average is below the 60-day average, a short-term downtrend.
Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.
Factor grades
Ranked against 2848 U.S. stocks StockVane covers.
Last computed: 2026-11-22 08:27 UTC
Data coverage: 5 of 6 factors. Missing data is not a zero score.
The radar needs all six factors. Available grades are shown below.
Valuation C-
How expensive the stock is versus earnings, sales and its own 5-year history.
| P/E (TTM) | 13.6x | Better than 63% |
| P/E vs own 5-yr range | 99th pctl | Better than 3% |
Growth N/A
How fast revenue, profit and free cash flow are compounding.
Not enough data to grade this factor.
Profitability F
How much profit the business keeps from each dollar of sales and capital.
| Return on equity | -91.6% | Better than 6% |
| Return on invested capital | -94.6% | Better than 2% |
Momentum C+
Recent price strength, skipping the latest month to avoid short-term noise.
| 3-month return | -24.7% | Better than 24% |
| 6-month return | -8.2% | Better than 42% |
| 12-month return (ex latest month) | 25.8% | Better than 65% |
| Distance below 52-week high | 39.4% | Better than 29% |
Financial Health A
Balance-sheet strength: leverage, liquidity and interest coverage.
| Current ratio | 13.0x | Better than 95% |
| Debt to assets | 0.0% | Better than 99% |
| Interest coverage | -4.3x | Better than 17% |
Analyst View A
What the Street thinks: share of Buy ratings and upside to the average target.
| Analysts rating Buy | 100.0% | Better than 77% |
| Upside to average target | 101.0% | Better than 84% |
Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.
Performance
Key statistics
Price & volume
- Prev close
- 24.30
- Open
- 23.81
- Day range
- 23.13 - 24.51
- Avg price
- 23.58
- Volume
- 643.38K
- Turnover
- 15.17M
- Turnover ratei
- 1.55%
- Volume ratioi
- 0.99
- Amplitudei
- 5.70%
- 52-week rangei
- 15.76 - 38.33
Valuation
- P/Ei
- -5.83
- P/E (TTM)i
- 13.58
- P/Bi
- 3.93
- EPSi
- -3.98
- Book value / shi
- 5.91
- Net profit
- -246.38M
- Net assets
- 365.80M
Share structure
- Market cap
- 1.44B
- Float capi
- 964.92M
- Shares out
- 61.90M
- Float sharesi
- 41.56M
Dividend & listing
- Div yield (TTM)i
- 0.00%
- Dividend (TTM)
- 0.00
- Listing date
- 1970-01-01
39.4% below the 52-week high
Trading activity
Net capital flow main funds, last 45 sessions
-4.02M net over the window
Short interest
- Shares short
- 4.69M
- % of floati
- 7.60%
- Days to coveri
- 10.66
- As of
- 2026-10-30
Frequently asked questions
What is the current stock price of Damora Therapeutics (DMRA)?
Damora Therapeutics last traded at 23.22. This page shows a periodic quote snapshot. Check the displayed quote time.
What is Damora Therapeutics's market cap?
About 1.44B.
What is the P/E ratio of Damora Therapeutics?
The trailing twelve-month P/E is 13.58. The Valuation tab shows it against the stock's own five-year range.
Does Damora Therapeutics pay a dividend?
Damora Therapeutics does not currently pay a regular dividend.
Is Damora Therapeutics a buy according to analysts?
The consensus of 6 analysts is a Buy rating, with an average 12-month price target of 46.67, which implies 101.0% upside from the current price. This is not investment advice.
What is Damora Therapeutics's StockVane Quant Rating?
The StockVane Momentum strategy currently rates Damora Therapeutics a D (Sell). Below its 200-day average or in the bottom third on momentum — the strategy is out of it. Not investment advice.
Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.
Damora Therapeutics discussion 0 comments